

AMENDMENTS

Listing of Claims

1-14. (Canceled)

15. (New) A peptide consisting of a cytotoxic T-cell epitope consisting essentially of the amino acid sequence QNGALAINTF (SEQ ID NO: 36).

16. (New) A peptide as claimed in claim 1 consisting of the amino acid sequence QNGALAINTF (SEQ ID NO: 36).

17. (New) A composition comprising the peptide as claimed in claim 1 in combination with an adjuvant.

18. (New) The composition of claim 3 wherein the adjuvant is montanide ISA 720.

19. (New) The composition of claim 3 wherein the adjuvant comprises Quillaia saponins, cholesterol and phospholipids.

20. (New) A composition comprising the peptide as claimed in claim 2 in combination with an adjuvant.

21. (New) The composition of claim 6 wherein the adjuvant is montanide ISA 720.

22. (New) The composition of claim 6, wherein the adjuvant comprises Quillaia saponins, cholesterol and phospholipids.

23. (New) The composition of claim 3, wherein said composition is a water-in-oil emulsion.

24. (New) The composition of claim 6, wherein said composition is a water-in-oil emulsion.

25. (New) A composition comprising the peptide as claimed in claim 1 or 2 in combination with at least one further T-cell epitope.

26. (New) A composition as claimed in claim 11 wherein the further T-cell epitope is selected from the group consisting of TSLYNLRRGTALLA (SEQ ID NO: 1), DTPLIPLTIF (SEQ ID NO: 2), TVFYNIIPMPL (SEQ ID NO: 3), VEITPYKPTW (SEQ ID NO: 4),

VSFIEFVGW [B] (SEQ ID NO: 5), FRKAQIQGL (SEQ ID NO: 6), FLRGRAYGL (SEQ ID NO: 7), QAKWRLQTL (SEQ ID NO: 8), SVRDRLARL (SEQ ID NO: 9), YPLHEQHGM (SEQ ID NO: 10), HLAAQGMAY (SEQ ID NO: 11), RPPIFIRRL (SEQ ID NO: 12), RLRAEAGVK (SEQ ID NO: 13), IVTDFSVIK (SEQ ID NO: 14), AVFDRKSDAK (SEQ ID NO: 15), NPTQAPVIQLHAVY (SEQ ID NO: 16), LPGPQVTAVLLHEES (SEQ ID NO: 17), DEPASTPEVHDQLL (SEQ ID NO: 18), RYSIFFDY (SEQ ID NO: 19), AVLLOHEESM (SEQ ID NO: 20), RRARSLSAERY (SEQ ID NO: 21), EENLLDFVRF (SEQ ID NO: 22), KEHVQNFAF (SEQ ID NO: 23), RRIYDLIEL (SEQ ID NO: 24), QPRAPIRPI (SEQ ID NO: 25), EGGVGWRHW (SEQ ID NO: 26), CLGGLLTMV (SEQ ID NO: 27), RRRWRRLTV (SEQ ID NO: 28), RAKFKQLL (SEQ ID NO: 29), RKCCRAKFKQLLQHYR (SEQ ID NO: 30), TYSAGIVQI (SEQ ID NO: 34) and LLDFVRFMGV (SEQ ID NO: 35).

27. (New) A composition as claimed in claim 11 selected from the group consisting of: (i) a composition comprising the cytotoxic T-cell epitopes QNGALAINTF (SEQ ID NO: 36) and LLDFVRFMGV (SEQ ID NO: 35); (ii) a composition comprising the cytotoxic T-cell epitopes QNGALAINTF (SEQ ID NO: 36) and FLRGRAYGL (SEQ ID NO: 7); and (iii) a composition comprising the cytotoxic T-cell epitopes QNGALAINTF (SEQ ID NO: 36) and TYSAGIVQI (SEQ ID NO: 34).

28. (New) A composition as claimed in claim 11 comprising the cytotoxic T-cell epitopes QNGALAINTF (SEQ ID NO: 36), FLRGRAYGL (SEQ ID NO: 7) AND EENLLDFVRF (SEQ ID NO: 22).

29. (New) A composition as claimed in claim 11 comprising the cytotoxic T-cell epitopes QNGALAINTF (SEQ ID NO: 36), FLRGRAYGL (SEQ ID NO: 7) AND QPRAPIRPI (SEQ ID NO: 25).

30. (New) A composition as claimed in claim 11 comprising the cytotoxic T-cell epitopes QNGALAINTF (SEQ ID NO: 36), FLRGRAYGL (SEQ ID NO: 7), EENLLDFVRF (SEQ ID NO: 22) and QPRAPIRPI (SEQ ID NO: 25).

31. (New) A composition as claimed in claim 11 further comprising at least one antigen against which an anamnestic is elicited.

32. (New) A composition as claimed in claim 17 wherein the antigen is selected from the group consisting of tetanus toxoid, a Bordatella pertussus antigen, a poliovirus antigen, a purified protein derivative (PPD), and EBV gp350 protein, and helper epitope.

33. (New) A composition as claimed in claim 17 wherein the antigen is tetanus toxoid.